Elanco Animal Health Incorporated Repayments of Senior Debt
Elanco Animal Health Incorporated (ELAN) reported Repayments of Senior Debt of $89.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSeniorDebt · last filed 2026-08-05
- Elanco Animal Health Incorporated repayments of senior debt for the quarter ending 2026-06-30 was $73.00M, a 79.78% decline year-over-year.
- Elanco Animal Health Incorporated repayments of senior debt for the quarter ending 2026-03-31 was $16.00M, a 23.08% increase year-over-year.
- Elanco Animal Health Incorporated repayments of senior debt for the quarter ending 2025-12-31 was $2.11B, a 16107.69% increase year-over-year.
- Elanco Animal Health Incorporated repayments of senior debt for the quarter ending 2025-09-30 was $188.00M, a 87.96% decline year-over-year.
- Elanco Animal Health Incorporated repayments of senior debt for fiscal 2025 was $2.67B, a 66.81% increase from fiscal 2024.
- Elanco Animal Health Incorporated repayments of senior debt for fiscal 2024 was $1.60B, a 298.01% increase from fiscal 2023.
- Elanco Animal Health Incorporated repayments of senior debt for fiscal 2023 was $402.00M, a 40.62% decline from fiscal 2022.
- Elanco Animal Health Incorporated repayments of senior debt for fiscal 2022 was $677.00M, a 18.15% increase from fiscal 2021.
| Period end | Repayments of Senior Debt 3 month | Repayments of Senior Debt 6 month | Repayments of Senior Debt 9 month | Repayments of Senior Debt 12 month | Repayments of Senior Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $73.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $89.00M 10-Q · filed 2026-08-05 | $2.20B derived: sum of 3 quarters · filed 2026-08-05 | $2.38B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $16.00M 10-Q · filed 2026-05-06 | $2.12B derived: sum of 2 quarters · filed 2026-05-06 | $2.31B derived: sum of 3 quarters · filed 2026-05-06 | $2.67B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $2.11B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $2.29B derived: sum of 2 quarters · filed 2026-02-24 | $2.66B derived: sum of 3 quarters · filed 2026-08-05 | $2.67B 10-K · filed 2026-02-24 | |
| 2025-09-30 | $188.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $549.00M derived: sum of 2 quarters · filed 2026-08-05 | $562.00M 10-Q · filed 2025-11-05 | $575.00M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $361.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $374.00M 10-Q · filed 2026-08-05 | $387.00M derived: sum of 3 quarters · filed 2026-08-05 | $1.95B derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $13.00M 10-Q · filed 2026-05-06 | $26.00M derived: sum of 2 quarters · filed 2026-05-06 | $1.59B derived: sum of 3 quarters · filed 2026-05-06 | $1.60B derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.57B derived: sum of 2 quarters · filed 2026-02-24 | $1.59B derived: sum of 3 quarters · filed 2026-02-24 | $1.60B 10-K · filed 2026-02-24 | |
| 2024-09-30 | $1.56B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.57B derived: sum of 2 quarters · filed 2025-11-05 | $1.59B 10-Q · filed 2025-11-05 | $1.60B derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $25.00M 10-Q · filed 2025-08-07 | $39.00M derived: sum of 3 quarters · filed 2026-02-24 | $395.00M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2024-03-31 | $13.00M 10-Q · filed 2025-05-07 | $27.00M derived: sum of 2 quarters · filed 2026-02-24 | $383.00M derived: sum of 3 quarters · filed 2026-02-24 | $396.00M derived: sum of 4 quarters · filed 2026-02-24 | |
| 2023-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $370.00M derived: sum of 2 quarters · filed 2026-02-24 | $383.00M derived: sum of 3 quarters · filed 2026-02-24 | $402.00M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $356.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $369.00M derived: sum of 2 quarters · filed 2024-11-07 | $388.00M 10-Q · filed 2024-11-07 | $458.00M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-06-30 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $32.00M 10-Q · filed 2024-08-08 | $102.00M derived: sum of 3 quarters · filed 2025-02-25 | $181.00M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2023-03-31 | $19.00M 10-Q · filed 2024-05-08 | $89.00M derived: sum of 2 quarters · filed 2025-02-25 | $168.00M derived: sum of 3 quarters · filed 2025-02-25 | $607.00M derived: sum of 4 quarters · filed 2025-02-25 | |
| 2022-12-31 | $70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $149.00M derived: sum of 2 quarters · filed 2025-02-25 | $588.00M derived: sum of 3 quarters · filed 2025-02-25 | $677.00M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $79.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $518.00M derived: sum of 2 quarters · filed 2023-11-07 | $607.00M 10-Q · filed 2023-11-07 | $625.00M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-06-30 | $439.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $528.00M 10-Q · filed 2023-08-07 | $546.00M derived: sum of 3 quarters · filed 2024-02-26 | $1.06B derived: sum of 4 quarters · filed 2024-02-26 | |
| 2022-03-31 | $89.00M 10-Q · filed 2023-05-09 | $107.00M derived: sum of 2 quarters · filed 2024-02-26 | $625.00M derived: sum of 3 quarters · filed 2024-02-26 | $642.00M derived: sum of 4 quarters · filed 2024-02-26 | |
| 2021-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $536.00M derived: sum of 2 quarters · filed 2024-02-26 | $553.00M derived: sum of 3 quarters · filed 2024-02-26 | $573.00M 10-K · filed 2024-02-26 | |
| 2021-09-30 | $518.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $535.00M derived: sum of 2 quarters · filed 2022-11-08 | $555.00M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $37.00M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $20.00M 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | $952.00M 10-K · filed 2023-03-01 | $951.50M 10-K · filed 2021-03-01 | |||
| 2019-12-31 | $121.00M 10-K · filed 2022-02-28 | $121.10M 10-K · filed 2020-02-28 | |||
| 2018-12-31 | $7.50M 10-K · filed 2021-03-01 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-28 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |